Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cann Group.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Biotech Stocks: Estia picks up 4 new aged care homes; MGC flags positive result for long COVID symptoms
Explainers
ASX Cannabis Stocks Guide 2022/23: Here’s everything you need to know
Health & Biotech
Weed Week: Aurora Marijuanis and CBD bubble tea in Thailand
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
Weed Week: Cannabis lounges in Las Vegas and Cann’s Mildura cannabis facility gets GMP licence
News
ASX Small Caps Lunch Wrap: Who else’s moonshot has crashed horribly today?
Health & Biotech
ASX Health Stocks: Cann’s Mildura cannabis facility gets GMP licence, unlocking export markets
Health & Biotech
Weed Week: Sydney Uni says it’s okay to CBD ‘n drive, and cannabis-infused drinks on the rise
Health & Biotech
Why millions of Aussie patients could be lining up for over-the-counter CBD… but not until 2023
News
Closing Bell: A fintech flyer as the ASX follows Wall Street into the red on Friday
Health & Biotech
Weed Week: US seed bank launches 4/20 day NFT collection and Washington has a cannabis tax holiday
Health & Biotech
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
Health & Biotech
Weed Week: Will the US Senate pass the MORE act, and Swiss cannabis wellness spas are a thing
Health & Biotech
ASX Health Stocks: Cann to market over-the-counter CBD capsules in Australia
Health & Biotech
ASX Health Stocks: UK FSA welcomes Cann’s CBD capsules onto its approved list
Health & Biotech
Weed Week: Wastewater doesn’t lie, Aussie cannabis consumption increased in 2021
Health & Biotech